Pfizer Inc. today announced data from its Phase 2 study (NCT06524414) evaluating the safety, tolerability and immunogenicity of a four-dose series of its investigational 25-valent pneumococcal ...
Investor's Business Daily on MSN
How S&P drug titan Pfizer plans to outdo its own $6 billion franchise
The next-generation version of Pfizer's $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study.
Pfizer Inc. said a new version of its bestselling Prevnar vaccine may provide infants with better protection against common ...
New data show breakthrough bleeds and surgery were successfully managed for people with hemophilia taking Hympavzi in a large ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results